Sana Biotechnology (NASDAQ:SANA) Trading 6.3% Higher – Still a Buy?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares rose 6.3% on Thursday . The company traded as high as $2.81 and last traded at $2.78. Approximately 943,825 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 10,019,388 shares. The stock had previously closed at $2.61.

Analyst Upgrades and Downgrades

SANA has been the subject of a number of recent analyst reports. HC Wainwright upped their target price on Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Finally, TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.25.

Sana Biotechnology Trading Down 0.8 %

The stock has a market capitalization of $578.27 million, a PE ratio of -1.85 and a beta of 1.59. The company’s 50 day simple moving average is $2.79 and its 200 day simple moving average is $3.49.

Insider Activity

In related news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares in the company, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 31.10% of the company’s stock.

Institutional Investors Weigh In On Sana Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cerity Partners LLC bought a new stake in shares of Sana Biotechnology in the fourth quarter worth $25,000. Tower Research Capital LLC TRC raised its position in shares of Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after buying an additional 10,548 shares in the last quarter. Syon Capital LLC acquired a new stake in Sana Biotechnology in the fourth quarter valued at about $27,000. Wilmington Savings Fund Society FSB bought a new position in shares of Sana Biotechnology in the 3rd quarter valued at $29,000. Finally, Ameriprise Financial Inc. bought a new stake in Sana Biotechnology during the 4th quarter worth approximately $29,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.